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ABSTRACT – Laboratory investigations, whilst not essential to the diagnosis
of seizures or of epilepsy, can be fundamental to determining the cause
and guiding management. Over 50% of first seizures have an acute symp-
tomatic cause, including a range of metabolic, toxic or infectious cause.
The same triggers can precipitate status epilepticus, either de novo or as
part of a deterioration in control in individuals with established epilepsy.
Some, such as hypoglycaemia or severe hyponatraemia, can be fatal without
prompt identification and treatment. Failure to identify seizures associated
with recreational drug or alcohol misuse can lead to inappropriate AED
treatment, as well as a missed opportunity for more appropriate interven-
tion. In individuals with established epilepsy on treatment, some laboratory
monitoring is desirable at least occasionally, in particular, in relation to
bone health, as well as in situations where changes in AED clearance or
metabolism are likely (extremes of age, pregnancy, comorbid disorders of
renal or hepatic function). For any clinician managing people with epilepsy,
awareness of the commoner derangements associated with individual AEDs
is essential to guide practice. In this article, we review indications for
tests on blood, urine and/or cerebrospinal fluid in patients presenting with
new-onset seizures and status epilepticus and in people with established
epilepsy presenting acutely or as part of planned monitoring. Important,
but rare, neurometabolic and genetic disorders associated with epilepsy
are also mentioned.
Key words: epilepsy, seizure, blood, CSF, therapeutic drug monitoring,
investigations
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ILAE Curriculum Primary Learning objective:
Decide which patients should receive laboratory
tests and which types of tests should be ordered
Sub-objectives:
• Blood and cerebrospinal fluid investigations in
people with new-onset seizures
• Blood and cerebrospinal fluid investigations in
patients with status epilepticus
• Utility of laboratory investigations in differentiat-
ing seizures from other events
• The role of blood tests, including therapeutic
monitoring in long-term management
he diagnosis and management of epilepsy, including
rst seizures and status epilepticus, depends largely on
horough history taking, including a forensic approach
o obtaining witness accounts and information about
he background and circumstances affecting an indi-
idual. Investigations, such as EEG and MRI, as will be
overed in separate articles in this series, and are of
articular value in identifying the type of epilepsy and
nderlying cause, and contributing to predicting risk
f recurrence after a first unprovoked seizure. How-
ver, at least 55% of new-onset seizures (Beghi et al.,
010), including around 50% of status epilepticus cases,
re provoked (acute symptomatic seizures). In patients
ith known epilepsy, systemic illnesses may also con-
ribute to deterioration in seizure control. It is in this
ontext that laboratory (blood, urine, cerebrospinal
uid) investigations are especially important. This
eview summarises the role of laboratory investiga-
ions in the diagnosis and management of people
resenting with seizures, to provide an educational
esource to help the managing clinician decide which
atients should receive laboratory tests and which
ypes of tests should be ordered. This is a core com-
etency (Level 1) defined in the ILAE Epileptology
urriculum (Blümcke et al., 2019), which is relevant for
ll health professionals involved in the diagnosis and
anagement of people with epilepsy.
irst seizure
lthough not key to the diagnosis of a first seizure,
r new-onset seizures, some laboratory investiga-
ions performed as soon as possible after the seizure
nset can be key to identifying the cause, specif-
cally with respect to determining if the event is82
rovoked (acute symptomatic) or unprovoked. Acute
ymptomatic seizures occur at the time of, or in close
ssociation with, a documented brain insult (Thurman
t al., 2011), which likely account for over 50% of all first
eizures (Hauser and Beghi, 2008). Importantly, with
n acute symptomatic seizure, the key priority in man-








apidly fatal, but if successfully managed, are associ-
ted with full recovery and a recurrence risk of less
han 3% (Pohlmann-Eden et al., 2006). In contrast, the
ve-year risk of recurrence is at least 10-fold higher fol-
owing a first unprovoked seizure (Marson et al., 2005).
hus, correctly distinguishing between provoked and
nprovoked at the outset has important implications
or the individual both in the first few hours and also
ith respect to longer-term management and safety
dvice including driving. Almost any acute brain insult,
ncluding stroke and trauma, can result in an acute
ymptomatic seizure, but in the context of this arti-
le, the most important triggers are metabolic, toxic,
nfectious and inflammatory.
etabolic: Metabolic derangements causing seizures
an be extremely dangerous and need to be treated
rgently, therefore checking (capillary and then
erum) glucose, sodium, calcium and magnesium and
enal and liver function should be done as soon as
ossible. These, and other essential initial tests, are
ummarized in table 1. The only exception is children
ith simple febrile seizures, for which there is consen-
us that additional investigations are not required
nless there are other clinical markers of concern
American Academy of Pediatrics, 2011; Wilmshurst et
l., 2015).
Glucose: In patients of any age, including neonates
or whom it is especially important (Gataullina et al.,
015), checking that the blood glucose is within nor-
al range should be of the utmost priority, as untreated
ypoglycaemia can rapidly lead to irreversible neuro-
ogical damage and death. In adults, a glucose level
elow 2 mM/L or above 25 mM/L is usually required to
roduce seizures, the latter most commonly in older
atients with type II diabetes, whereas hyperglycaemia
ccompanied by ketosis is not usually epileptogenic
Nass et al., 2017; Ohara et al., 2017). Additionally,
iabetes mellitus is an independent risk factor for
eizures in the elderly, therefore HbA1c (glycosylated
aemoglobin) testing should be performed in older
atients as a measure of longer-term blood glucose
Baviera et al., 2017).
Sodium: Hyponatraemia is the commonest elec-
rolyte disturbance to provoke seizures in adults.
he mechanism for this is cerebral oedema, which
s due to the osmotic gradient between the plasma
nd the brain. The more rapid the fall in sodium,
he fewer adaptive responses the brain can produce
o protect itself and more severe the resulting cere-Epileptic Disord, Vol. 22, No. 4, August 2020
ral oedema will be. Whilst less common, children
re particularly vulnerable to the effects of cerebral
edema as they have relatively large brains compared
o their scull size (Nardone et al., 2016). Correction
f low sodium must be carefully monitored to avoid
he potentially devastating complication of pontine
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Laboratory investigations in epilepsy
Table 1. Essential laboratory investigations after a first seizure, ideally within 24 hours*.
Parameter May provoke acute symptomatic seizure
METABOLIC TRIGGERS Lower limit Upper Limit
Glucose ≤2 mM/l (36 mg/dl) >25 mM/l (450 mg/dl)
HbA1c
Sodium ≤115 mM/l (50 mg/dl) ≥160 mM/l (70 mg/dl)
Calcium ≤1.2 mM/l (5.0 mg/dl) ≥3.0 mM/l (12.0 mg/dl)
Magnesium ≤0.3 mM/l (0.73 mg/dl)
Urea or




Creatinine >884M/l (10 mg/dl)
OTHER Rationale
Liver function tests May indicate systemic disease or alcohol abuse
Full blood count May indicate infection (raised white blood cell count) or alcohol abuse
(raised mean corpuscular volume)


























































Serum alcohol level Detectable levels ind
Urinary drug screen Detectable levels ma
bA1c: glycosylated haemoglobin. *All investigations should be
4 hours following the index event, a causal relationship between
yelinolysis. Hypernatraemia is a much less common
ause of seizures but may produce them due to brain
hrinkage (Castilla-Guerra et al., 2006).
Calcium and magnesium: Hypocalcaemia, and less
requently hypercalcaemia, can provoke seizures.
hen this is identified, further investigations as to the
ause, usually in consultation with an endocrinologist,
ay also be required, which is beyond the scope of
his article. Hypomagnesaemia is much less common
ut can cause seizures in any age group.
Potassium: Derangements in serum potassium are
learly very dangerous from a cardiovascular and neu-
omuscular perspective, and so important to identify,
ut do not cause central nervous system (CNS) symp-
oms or seizures (Riggs, 2002; Castilla-Guerra et al.,
006).
Urea, nitrogen and creatinine: Seizures are common
n patients with renal failure due to elevated urea. It
hould be noted that non-convulsive status and status
pilepticus may mimic uremic encephalopathy, there-
ore it is particularly important to consider these as
ossible diagnoses in renal patients (Titoff et al., 2019).
nfective and inflammatory disease: Infective or inf-pileptic Disord, Vol. 22, No. 4, August 2020
ammatory causes should be considered in any one
ith a history of fever or recent malaise, and untreated
an prove fatal. Febrile seizures are particularly com-
on in children up to school age, but seizures can
e the presenting feature of infection or inflamma-








icate recreational drug use
ested urgently, as soon as the patient presents. After more than
bnormalities and the seizure cannot be definitively established.
full blood count (FBC) and test for C-reactive pro-
ein (CRP) as a minimum. Mild leucocytosis and raised
RP are commonly found postictally due to a gener-
lised inflammatory response, with a lack of evidence
o define clear levels above which a more aggressive
earch for infection should follow. Further investiga-
ions will depend on the clinical history, examination,
bservations and sometimes repeated laboratory tests
o look for trends. If there are clinical reasons to
uspect a central nervous system infection or sepsis
which can itself be associated with an encephalopa-
hy), blood and urine cultures, and cerebrospinal fluid
CSF) samples should be obtained. In any patient
ith focal signs or who has not completely recov-
red, brain imaging (typically brain CT) will be needed
efore CSF can be collected (indications for brain
maging in epilepsy are covered in a separate arti-
le). CSF opening pressure should be recorded (for
xample, venous sinus thrombosis can present with
eizures and a high opening pressure), and CSF sent for
outine tests including cell count, protein, sugar
with matched blood sugar), bacterial culture and
iral PCR. Depending on the clinical history and
xamination, additional tests for fungal or mycobac-383
erial infections, and oligoclonal bands, might also
e appropriate. It is sensible to take more than
equired for initial tests, with a saved sample for
dditional tests, should they be required based on
nitial results, or other information that emerges
ater.
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n persons presenting with behavioural changes,
emory problems, a high frequency of new-onset
eizures or (as will be covered later) status epilep-
icus, if other tests have been non-contributory, the
ossibility of an autoimmune encephalitis needs to
e considered. This should be investigated alongside
pecific serum and CSF antigens (Dalmau and Graus,
018). If there is any suspicion of multiple sclerosis,
hen oligoclonal bands may also be important. Clini-
al treatment decisions usually have to be made before
he results of these additional investigations are avail-
ble (this can take 2-3 weeks, even in well-resourced
ettings), further discussion of which is beyond the
cope of this article, but decision-making algorithms
ave been created to aid this (Graus et al., 2016; Wagner
t al., 2018).
ntoxication: In parallel with assessing for metabolic
nd infectious causes of a first seizure, one should
onsider whether recreational drugs, alcohol or med-
cations may have been precipitants. It is not possible
o provide absolute cut-off thresholds for these, as
nter-individual differences in seizure susceptibility
lay a substantial role (Brathen et al., 2005), but the
etection of substances at all in the appropriate time
indow may be highly relevant. Importantly, when
rug or alcohol-provoked seizures are identified, co-
orbid epilepsy, sometimes as yet undiagnosed, is not
ncommon and the recurrence risk (due to recurrent
ngestion or epilepsy) is also higher, therefore addi-
ional investigations as for any first unprovoked seizure
EEG and MRI) should still be undertaken at a later date.
Alcohol: Alcohol withdrawal, particularly in combi-
ation with sleep deprivation, is a very common cause
f seizures. Seizures usually occur 6-48 hours after ces-
ation of drinking (Leach et al., 2012). As markers of
hronic alcohol consumption, mean corpuscular vol-
me (MCV) and serum gamma glutamyl transferase
GGT) may be useful, although the latter may be ele-
ated due the ingestion of certain drugs, including
any antiepileptic drugs (AEDs).
Benzodiazepines and recreational drugs: A broad
ange of widely available, though mostly illegal,
timulant drugs can cause seizures even at low lev-
ls of consumption. Cocaine, crack, normeperidine,
eperidine, methaqualone, glutarimide, ethylene-
ioxymethamphetamine and a range of other synthetic
timulants are considered high risk, along with phen-
yclidine and quatadine (Beghi et al., 2010). Other
rugs with narcotic effects, such as benzodiazepines,84
ynthetic cannabinoids, gamma-hydroxybutyrate and
piates including heroin, may trigger seizures during
heir withdrawal (Leach et al., 2012). The use of multiple
ntoxicants is common, so rather than testing for indi-
idual agents, urinary drug screening for metabolites







Prescription medications: Drugs such as antibiotics,
ntidepressants and antipsychotics in routine use
arely induce seizures, even in people with epilepsy
ther than in the context of significant overdoses.
sually patient history is sufficient, but to identify
ntoxication or slow metabolizers, serum drug moni-
oring may be useful.
as it a seizure? Diagnostic uncertainty. A number
f laboratory investigations have also been proposed
s potentially useful where there is diagnostic uncer-
ainty as to the nature of an event, specifically to
iscriminate between epileptic seizures, psychogenic
on-epileptic seizures (PNES) and syncope. However,
hilst of academic interest, none should be consid-
red diagnostic and, in most instances, will not be
seful. Many of these markers are only raised in tonic-
lonic seizures, and even then, they are not wholly
eliable as summarized below. Clinical history and wit-
ess accounts remain the mainstay in the diagnosis of
pileptic seizures.
Prolactin is the most widely suggested but has sub-
tantial limitations: It is only useful when there is a
nown (pre-event) baseline and taken 20 minutes post-
vent, which is rarely achievable. It does not always
ise after an epileptic seizure; it may rise due to other
vents such as syncope and its levels depend on
any other variables including age, gender, circadian
hythm, medications, pregnancy and even psycholog-
cal stress. In status epilepticus, prolactin levels may
ormalise after an initial rise (Abubakr and Wambacq,
016; Nass et al., 2017).
Creatinine kinase (CK): A transitory (sometimes very
ubstantial) increase in creatinine kinase, 24-72 hours
fter a tonic-clonic seizure (TCS), is a relatively specific
ut not sensitive marker (i.e. raised CK points towards
TCS, but a normal CK does not rule it out). How-
ver, it should be noted that CK may be elevated due
o other conditions such as a post-syncopal long lie.
evertheless, a raised CK is important to help iden-
ify patients who will be at higher risk of developing
cute kidney injury as a result of muscle breakdown
ue to seizures, and these patients will need careful
onitoring and treatment if this develops (Nass et al.,
017).
Ammonia: A transitory increase in ammonia, lasting
-8 hours after an event, is a relatively specific but not
ensitive marker of a convulsion. Patients with cirrho-
is and no history of convulsions will have persistently
levated ammonia. Valproic acid may also cause eleva-Epileptic Disord, Vol. 22, No. 4, August 2020
ions in serum ammonia (Nass et al., 2017).
Lactate: A raised lactate level above 2.45 mmol/L,
aken within two hours of the event, has been postu-
ated to be a useful indicator of a likely TCS. However,
his is not very sensitive (Matz et al., 2016). Further-
ore, simulated seizures can also produce markedly



































































































aised lactate levels (Lou Isenberg et al., 2020). There
re also numerous other causes of a raised lactate level,
uch as sepsis, tumour or liver disease, therefore this
annot be considered diagnostic in isolation.
ther parameters in infants: In infants (under one year)
ith new-onset seizures (also covered below), ide-
lly, the genetic syndrome of pyridoxine-deficiency
pilepsy should be excluded (van Karnebeek et al.,
016) based on determination of alpha-aminoadipic
emialdehyde/pyrroline 6’ carboxylate (in urine,
lasma or cerebrospinal fluid) and ALDH7A1 molec-
lar analysis.
tatus epilepticus
n the previous sections we discuss what to test the first
ime someone presents with seizures, and the limited
tility of laboratory testing in the case of diagnostic
ncertainty. In this section, we discuss what labora-
ory tests to perform in the patient who does not stop
eizing, i.e. presents with status epilepticus (SE). As
ith any seizure, the diagnosis of status epilepticus
s primarily a clinical one, supported, when possible,
y neurophysiological (EEG) data (Trinka et al., 2015).
he role of laboratory testing is, as with first seizures,
o identify the cause but also, particularly in convul-
ive SE, to evaluate the possible consequences of what
s a life-threatening medical emergency, to inform on
ngoing management. A suggested approach to labo-
atory testing for SE is summarized in figure 1.
or all patients: All patients in SE should have the
andatory blood tests described in table 1. In addition,
oagulation studies and creatine kinase, an arterial
lood gas and toxicology screening should be per-
ormed. This is to establish a baseline, as part of
nvestigating the cause, and to identify those who
ight be at particularly high risk of complications, such
s those with acute kidney injury (from rhabdomyoly-
is) or a coagulopathy.
atients with known epilepsy: An antiepileptic drug
AED) level must be checked as low AED levels are the
ost common cause of SE in this group of patients
Trinka et al., 2012). Ideally, AED levels should be tested
n a sample taken prior to any AED administration.
n practice, as relevant background information maypileptic Disord, Vol. 22, No. 4, August 2020
ot be available at the point of presentation, it is sen-
ible to take an additional 5 mL of serum saved for
uture testing at the outset, before AEDs given as part of
reating the episode confound interpretation. Specific
ED levels can then be requested for the original sam-
le at a later date when prescribed drugs are known.
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s not-detected, indicating poor adherence, though
eyond that the results should be interpreted with
aution, ideally compared to the individual’s own
herapeutic concentration as this may vary from the
tandard reference ranges (Lunardi et al., 2019). Thera-
eutic drug monitoring is not routinely recommended
uring SE treatment as AED concentrations may actu-
lly exceed the published target concentrations (NICE,
012 [Update 2019]), other than in refractory or super-
efractory cases in which confirming at least adequate
evels before an agent is considered ineffective can be
seful.
nfectious disease: Lumbar puncture should be per-
ormed in any patient with a suspicion of CNS infection
r inflammation or in any patient without another
lear cause of SE. A CSF pleocytosis of greater than
× 106/L is not usually caused by SE alone, and so this
hould prompt careful investigation of any infectious
r inflammatory cause (Frank et al., 2012; Scramstad
nd Jackson, 2017; Johnson et al., 2014). Testing for HIV
s also important to consider if not already known.
ommon infectious causes of SE are bacterial (e.g.
eningococcus, pneumococcus and haemophilus),
iral (e.g. herpes simplex 1 and enteroviruses) or pro-
ozoal (Lowenstein et al., 2014; He et al., 2016). There
s considerable regional variation in likely infectious
auses of SE, for example Japanese encephalitis is
ndemic in South-East Asia, malaria in sub-Saharan
frica and Asia, and neurocystericosis in Latin Amer-
ca, India and Africa, therefore the country of origin
nd travel history will impact on choice of labora-
ory investigations. HIV-positive patients will need a
ore comprehensive workup to exclude opportunis-
ic infections (Solomon et al., 2012).
mmunological & inflammatory disease: Autoimmune
ncephalitis (AE) is an uncommon but potentially treat-
ble cause of SE. Identifying it is of vital importance
ecause it may be associated with AED-refractory
eizures that will only improve with immunother-
py or, in the case of paraneoplastic encephalitis,
ith treatment of the underlying cancer. Our knowl-
dge of the autoimmune encephalitides and the
ntibodies associated with them is relatively recent
nd continues to evolve (Dalmau and Graus, 2018).
ultiple anti-neuronal antibodies may be implicated,
ncluding, likely, some yet to be discovered, with a
ange of presentations. Those most frequently asso-
iated with seizures and status epilepticus include:385
ntibodies against the GluN1 subunit of the NMDA
N-methyl-D-aspartate) receptor and anti-GAD, anti-
ABA (gammaaminobutyric acid) type A and B
eceptor, anti-LGI1 receptor (leucine-rich glioma inac-
ivated 1), and anti-Hu antibodies (Jacobs et al., 2003;
ohnson et al., 2010; Lancaster et al., 2010; Illingworth et
Journal Identification = EPD Article Identification = 1191 Date: September 8, 2020 Time: 10:37 am
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Status Epilepticus
All mandatory tests as per Table 1 plus:
coagulation studies, ABG, urine toxicology screen, blood alcohol level, 5ml serum saved












CSF : opening pressure, cell count, protein, paired serum & CSF glucose,
MC&S, viral PCR (HSV 1&2 , VZV, enteroviruses), lactate & saved sample
Serum HIV antibody testing
Serum and CSF autoimmune
encephalitis antibody testing
CJD → CSF 14-3-3 protein
MS or Rasmussen’s → paired oligoclonal bands
Autoimmune thyroid encephalopathy → TFTs, anti-thyroid Ab & antimicrosomal Ab
Sjogren syndrome → Immunoglobulins, RF, ANA, anti-SSA, SSB
Genetic or mitochondrial disease → serum & CSF lactate, specific genetic testing or
tests for inborn errors of metabolism
More extensive
viral PCR on CSF
As per specific risk factors:
HIV +ve → test for EBV, CMV, TB, Listeria, Crytococcus,
Toxoplasma, & syphilis
Immunosuppression → CSF fungal cultures; AFB,
toxoplasmosis testing (serum antibody and/or CSF PCR),
JC virus;
Risk factors for TB infection → CSF TB staining & culture
Travel to Malaria endemic regions → Malaria testing
Travel to Taenia solium endemic regions →
Neurocysticercosis testing






Has a clear precipitant of SE been identified?
Is there any reason to suggest additional dual
pathology that might change management?
Are there risk factors for more
unusual infections?
Is there :
-  a CSF lymphocytic pleocytosis (>5×106
   WBC/L) with no evidence of infection
-  refractory SE?











-  Inadequate AED levels (if known to have epilepsy)
Figure 1. Laboratory testing for status epilepticus.
Ab: antibody; ABG: arterial blood gas; AED: antiepileptic drug; AFB: acid fast bacilli; ANA: antinuclear antibody; CMV: cytomegalovirus;
CSF: cerebrospinal fluid; EBV: Epstein Barr virus; HIV: human immunodeficiency virus; HSV: herpes simplex virus; L: litre; MC&S:
microscopy, culture and sensitivities; PCR: polymerase chain reaction; RF: rheumatoid factor; SSA, SSB: Sjogren syndrome related
antigens types A and B ; TB: tuberculosis; TFT: thyroid function tests; VZV: varicella zola virus; WBC: white blood cells.







































































































l., 2011; Suleiman et al., 2011; Bien, 2013; Petit-Pedrol et
l., 2014). Any patient with a history of new-onset cogni-
ive or memory deficits, speech problems, movement
isorder or behavioural changes leading up to the SE,
hen no other obvious cause is identified, should be
nvestigated for autoimmune encephalitis. In practice,
ather than requesting full panels for all patients, dis-
ussion with the local laboratory, to agree priorities
nd understand local techniques and their sensitivity
nd specificity which can vary, is recommended. Anti-
AD (glutamic acid decarboxylase) antibodies are also
ot uncommonly identified, but also found in a range
f other disorders including diabetes, and of uncer-
ain pathogenicity (Alexopoulos and Dalakas, 2013).
SF will usually show a mild pleocytosis, but it may
e normal. Both serum and CSF should be tested for
ntibodies (Graus et al., 2016). For further guidance on
hen to investigate for AE, see figure 1. A diagnosis
f Hashimoto’s encephalopathy may be considered
n patients who have no anti-neuronal antibodies in
erum and CSF. These patients should be investigated
ith thyroid function tests, and serum thyroid perox-
dase and thyroglobulin antibodies, in order to assess
f they meet the diagnostic criteria. In patients who
re negative for anti-neuronal antibodies, and do not
eet the criteria for Hashimoto’s encephalopathy, fur-
her antibody testing in research laboratories for new
ntibodies may be considered, and the patient may be
valuated for the diagnosis of auto-antibody-negative
ut probable autoimmune encephalitis (Graus et al.,
016). Systemic autoimmune conditions may also
ause SE, including Sjogren’s and systemic lupus ery-
hematosus, and serum autoantibody testing may be
seful in these cases. SE can also occur in the context
f multiple sclerosis and Rasmussen’s encephalitis,
ut almost never as the presenting symptom. If there
s clinical suspicion of either of these inflammatory
onditions, then testing of serum and CSF oligoclonal
ands may be supportive in diagnosis.
ryptogenic new-onset refractory status epilepticus
NORSE) and what may be a subtype of the same
ondition, febrile infection-related epilepsy syndrome
FIRES), are characterised by the rapidly progressive
nset of seizures and encephalopathy that evolve into
rolonged super-refractory SE over a few days. In the
ase of FIRES, this is preceded by a minor febrile infec-
ion (Gaspard et al., 2018). Both are thought to have an
nflammatory/autoimmune basis, possibly involving a
ost-infection cytokine-medicated mechanism. Therepileptic Disord, Vol. 22, No. 4, August 2020
re currently no diagnostic laboratory tests for these
onditions.
enetic, mitochondrial and other disorders: There are
number of mitochondrial diseases which, though
are, have SE as a prominent feature. These include:
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cidosis, and stroke-like episodes (MELAS); Leigh syn-
rome; and myoclonic encephalopathy with ragged
ed fibres (MERRF) (Trinka et al., 2012; Myers et al.,
019). For these patients’ serum and CSF, testing for
actate is recommended, though alone, this neither
roves nor excludes a mitochondrial disorder, and
here there is a strong clinical suspicion, specialist
dvice should be sought. Inborn errors of metabolism,
uch as porphyria, Wilson’s disease and Alexander’s
isease, as well as chromosomal aberrations such as
ngelman syndrome, may be investigated with specific
enetic and/or laboratory testing. A comprehensive list
f all the genetic and mitochondrial disorders which
ay cause SE is beyond the scope of this article, but
overed in Myers et al (2019).
ole of blood tests in long-term
onitoring
ome authorities suggest laboratory tests should ide-
lly be performed prior to initiation of, and during
reatment with, almost any AED (Patsalos and St. Louis,
018). In most instances, some baseline parameters
ill nevertheless be available as part of an initial
nvestigation of the presenting seizure or associated
llness. Beyond that, the only other recommended
re-treatment test (table 2) is when treatment with
arbamazepine, oxcarbazepine or eslicarbazepine is
onsidered in individuals of Southeast Asian descent.
he human leucocyte antigen (HLA) allele, HLA-
*1502, is highly prevalent in this population (up to
5% in Hong Kong, Thailand and the Philippines), and
trongly associated with severe cutaneous hypersen-
itivity reactions (Stevens Johnson syndrome, toxic
pidermal necrolysis). For carbamazepine, hetero-
r homozygosity is estimated to show 98.3% sen-
itivity and 97% specificity for the development of
JS/TEN, with a 100% negative predictive value. Guide-
ines for screening prior to treatment are now in
lace in several developed countries (Fowler et al.,
019), though simply avoiding these drugs when
lternatives are readily available is also of course
ntirely appropriate. A number of other alleles have
lso been identified, but none with such a strong
ssociation.
ccording to most practitioners and guidelines, reg-
lar (e.g. annually or more) blood test monitoring of
hildren or adults with epilepsy is not recommended387
s routine and should only be performed if clinically
ndicated (NICE, 2012 [Update 2019]). Infrequent mon-
toring, e.g. at 2-5-year intervals, is almost certainly
ufficient. That said, awareness of the more common
otential laboratory abnormalities associated with
ED use is important. Patients need to be advised
o seek medical advice if indicative symptoms occur,
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Table 2. Recommended investigations in relation to antiepileptic drug use.
Antiepileptic drug Essential pre-treatment To be considered during treatment if there




Carbamazepine HLA-B*1502 in people of Southeast
Asian descent
Full blood count, liver function,
renal function
Clobazam Full blood count, liver function
Clonazepam Full blood count, liver function
Eslicarbazepine HLA-B*1502 in people of Southeast
Asian descent
Liver function, renal function, sodium
Ethosuximide Full blood count
Felbamate3 Full blood count, liver function3
Gabapentin
Lacosamide Liver function, renal function
Lamotrigine Full blood count, liver function
Levetiracetam





Phenytoin Liver function, renal function
Pregabalin Renal function
Rufinamide Liver function, renal function
Stiripentol Full blood count, liver function,
renal function
Topiramate Bicarbonate1
Valproate Full blood count, liver function
Vigabatrin Fll blood count, liver function, renal
function
Zonisamide Bicarbonate1
1To be considered in all children or cognitively impaired patients who may not be able to describe symptoms. 2Newly licensed,
recommended regular testing pre-initiation, after dose change and during maintenance; see summary of product characteristics.
3High-risk, sometimes, fatal reactions, recommended within the first month and no less than three-monthly thereafter. Liver function
should include aspartate transaminase (AST), alanine transaminase (ALT), bilirubin, alkaline phosphatase, and may include gamma
glutaryl transaminase. Renal function should include urea, sodium, potassium, and creatinine and may include bicarbonate and
chloride. Also, 25-hydroxy vitamin D should be considered in all patients, as covered in the text.








































































































nd non-specialists need to know which specific
bnormalities to test for depending on the AED in
uestion, and the clinical situation. It is similarly just
s important to know what minor derangements can
e safely attributed to AED use, without needing
ny change in treatment or further investigation.
road recommendations by drug are summarized
n table 2.
aematologic reactions: Many AEDs are associated
ith a spectrum of haematological side effects. These
nclude aplastic anaemia (carbamazepine, valproate
nd phenytoin), megaloblastic anaemia (phenytoin,
henobarbital and primidone) and thrombocytopa-
nia (carbamazepine and valproate). Transient leuko-
aenia and neutropaenia may also occur, especially in
atients with low pre-treatment levels. Clinical indi-
ations to test include the development of a sore
hroat/bacterial infection within a few weeks of start-
ng or a dose increase, new bleeding or bruising, or
xcessive fatigue. Second and third-generation AEDs
end to be associated with fewer haematological side
ffects, but for newer drugs, it must not be forgot-
en that rare but potentially dangerous effects can
ometimes only become apparent some years after
icensing. For all AED therapy, discontinuation is usu-
lly not indicated, unless symptoms are severe. In
eneral, withdrawal should be considered if cell count
alls below: 2,000/mL for white blood cells, 1,000/mL for
eutrophils, 3.5 × 106/mL for red blood cells (11 g/dL
or haemoglobin concentration) and 80,000/mL for
latelets (Verrotti et al., 2014). Overwhelmingly, haema-
ological reactions are reversible after withdrawal and
o not need any special treatment (Callaghan et al.,
985).
lectrolytes and pH changes: Hyponatremia is a com-
on finding with carbamazepine, oxcarbazepine and
slicarbazepine treatment, most likely due to antid-
uretic effects. It is usually mild (>130 mmol/L) and
symptomatic, though often causes undue concern if
icked up incidentally. Concurrent use of other agents,
uch as antihypertensives and serotonin re-uptake
nhibitors, increases the risk. Levels between 125 and
30 nmol/L (moderate), particularly when chronic, may
lso appear to be asymptomatic, though can also
e associated with subtle symptoms and increased
orbidity and mortality in some contexts. Symp-
oms, when present, range from minor unsteadiness,
alls, and reduced concentration through to confu-pileptic Disord, Vol. 22, No. 4, August 2020
ion, nausea, and in severe cases, life-threatening
ardiorespiratory distress or coma (Williams et al.,
016). Thorough clinical assessment is essential, with
anagement of symptoms (or lack of) being a more
mportant factor than absolute sodium. Additional
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re indicated in all but the mildest cases to exclude
nd address other contributors and inform decisions
bout the suspect AED. Asymptomatic metabolic (renal
ubular) acidosis is common during topiramate treat-
ent (Garris and Oles, 2005), and also seen with other
arbonic anhydrase inhibitors, zonisamide (Baulac et
l., 2014) and acetazolamide (Hamed, 2017). In some,
his is likely associated with an increased the risk of
ephrolithiasis (Kuo et al., 2002; Hamed, 2017) and a
rystalline nephropathy, although not all studies sup-
ort this (Shen et al., 2015).
epatotoxicity: Use of many AEDs, especially older
rugs such as phenytoin, carbamazepine and val-
roate (Bjornsson, 2008; Hamed, 2017), as well as
ome of the newer agents including cannabidiol,
s associated with abnormalities of liver function.
ild derangements based on liver function tests
<double the normal upper limit of normal) are
sually not of concern unless symptomatic or
eteriorating on repeat testing. Valproate use also
auses raised ammonia levels, sometimes causing
reversible encephalopathy (Chopra et al., 2012),
hough, of note, a non-hyperammonaemic valproate
ncephalopathy is also recognized. Testing should
e considered in any patient presenting with confu-
ion, lethargy or drowsiness after initiation or a dose
ncrease.
one health: An increased risk of fracture related
o AED use is now well established (Theochari and
ock, 2018). Whilst a broad range of parameters such
s markers of bone turnover have been evaluated
n research studies, the only laboratory measure
ndependently associated with fracture risk is vitamin
. AED use and epilepsy are both risk factors for
ypovitaminosis D, with likely pharmacological and
ther contributors (e.g. reduced sunlight exposure,
ower physical activity). Current evidence supports
esting serum vitamin D, calcium, albumin and alka-
ine phosphatase (“bone profile”), 2-5 times yearly
n adults and children on AEDs (NICE, 2012 [Update
019]), with vitamin D supplementation as required,
iming for a yearly average serum level of >50nmol/L
Dobson et al., 2018). Most of the evidence relates
o enzymes inducing older AEDs, specifically carba-
azepine, phenytoin and barbiturates, in whom more
requent monitoring (e.g. annually) may be justified
Arora et al., 2016). However, there is no doubt that
alproate (and enzyme inhibitor) is also implicated389
MHRA, 2009), and the paucity of evidence against
ewer AEDs may just reflect less cumulative exposure
nd should not be considered to indicate a lack of risk.
t is reasonable to assume, unless proven otherwise,
hat other enzyme inducers carry at least similar
isks, and other AEDs may carry some risk, though
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ome reassuring data with respect to lamotrigine and
evetiracetam is emerging (Theochari and Cock, 2018).
ardiovascular risk factors; Obesity, diabetes and
ypercholesterolaemia are all independently asso-
iated with cardiovascular disease and premature
ortality. These risks apply as much to people with
pilepsy as to others in the population. Several
ntiepileptic drugs can be associated with weight gain,
n particular, valproate, pregabalin, gabapentin, and
igabatrin, in whom monitoring of lipid profile and glu-
ose may be appropriate and inform lifestyle change,
r in some instances, a change in AED. In recent years,
nterest in the potential for AEDs to influence other
irculatory markers of vascular risk, such as homo-
ysteine, folate, C-reactive protein, and more recently,
omoarginine and asymmetric dimethylarginine, has
lso emerged (Kim et al., 2013; Sarecka-Hujar et al.,
019). However, the clinical implications of this in prac-
ice remain uncertain, with insufficient evidence as yet
o guide a monitoring or intervention strategy.
herapeutic drug monitoring: Therapeutic drug mon-
toring (TDM) is a tool which, correctly utilized, can
e extremely helpful in optimizing treatment for some
ndividuals. Certainly for many drugs, there is a bet-
er correlation between serum levels and efficacy than
ith the oral dose (Patsalos et al., 2018). However, for
he vast majority of patients, if they are free of seizures
nd side effects, Class I evidence now supports that
nowing the serum level is of little, if any, benefit in
outine practice (Aícua-Rapún et al., 2020). Thus, tak-
ng costs into account, routine monitoring is generally
ot recommended (NICE, 2012 [Update 2019]). TDM
an, however, be critical to support (or refute) a sus-
icion of non-adherence or for suspected toxicity or
eizure persistence despite prescribing of an adequate
ose (to identify fast metabolisers or non-compliance),
hen a formulation change is to occur and when phar-
acokinetic variability is expected (e.g. in children
r the elderly, pregnancy, or for hepatic or renal dis-
ase), or drug interactions are anticipated (Patsalos et
l., 2018). This is particularly so with phenytoin (which
xhibits saturation kinetics, meaning even a small
hange in dose or metabolism can result in substan-
ial changes in level), and in situations where reliance
n clinical judgement alone is felt to be insufficient, for
xample, when even a single, potentially preventable
eizure, after a period of remission, might have signif-
cant consequences. In this situation, if available, the90
est comparator is the “individual therapeutic concen-
ration”, i.e. a plasma AED concentration trough level
aken during a time of optimum therapeutic response
n an established dose. Individualized therapeutic
ED monitoring is accepted as much more meaningful







t al., 2018). Strictly speaking, predicting drug adher-
nce or non-adherence based on AED plasma levels
s only possible when the level is compared to that
ndividual’s therapeutic concentration (Lunardi et al.,
019), though in practice reasonable inferences can
e drawn from big fluctuations or undetectable levels
espite stable prescribed doses.
nown epilepsy with deterioration
f control
frequent clinical challenge is represented by people
ith established epilepsy presenting to acute medical
ervices, reporting a deterioration in seizure control.
his might be a single unprovoked seizure after a
eriod of remission, a reported increase in seizure
requency, or seizure clusters sometimes escalating
nd leading to concern about imminent status epilep-
icus. In this situation, it is important to remember that
ll the factors discussed earlier that can trigger acute
ymptomatic seizures, or status epilepticus, can sim-
larly influence seizure frequency in individuals with
stablished epilepsy, therefore a similar approach to
aboratory testing is recommended. Excluding inter-
urrent infection, as well as checking AED levels and
lcohol and toxicology screens can be key, yet the latter
n our experience are often overlooked in favour of CT
r even EEG, which are rarely informative or indicated
n this context.
regnancy in women with epilepsy
pecific issues pertain to women with epilepsy who
ight become or who are pregnant:
Some AEDs are known to have teratogenic effects
nd so choice and optimization of drug treatment in
dvance of any potential pregnancy in women of child-
earing age is particularly important (Tomson et al.,
019).
Non-adherence rates are increased during preg-
ancy (likely due to concerns over teratogenicity as
ell as other factors such as vomiting) (Schmidt et al.,
983). Therefore, pre-pregnancy counselling regarding
he importance of treatment continuation, because of
he maternal and foetal risks of uncontrolled seizures,
s extremely important (Pennell, 2003).
Serum levels of most AEDs fall during pregnancy
ue to haemodilution, changes in absorption and
etabolism and increased excretion.Epileptic Disord, Vol. 22, No. 4, August 2020
Whilst the seizure frequency of most women will
emain unchanged or fall during pregnancy, a signif-
cant number of them will experience an increase in
eizures, likely due to medication non-compliance and
educed serum levels (Harden et al., 2009; Pennell,
003).






































































































n light of the above issues, the question arises as
o the utility of therapeutic drug monitoring (TDM)
uring pregnancy, and to some, identifying a pre-
regnancy individual therapeutic concentration and
hen monitoring and adjusting the dose during preg-
ancy may seem like an obvious strategy. However,
n the only study to date to formally address this in
prospective and blinded manner, there was no evi-
ence to support “treating the level” over and above
tandard practice (increasing the dose in response
o changes in seizure frequency) (Thangaratinam et
l., 2018). An exception to this might be lamotrigine
hich exhibits markedly increased clearance during
regnancy, resulting in a reduction of plasma lev-
ls of around 65% in the second and third trimester
Petrenaite et al., 2005). There is some evidence that
DM of lamotrigine during pregnancy may be supe-
ior to clinical monitoring alone in reducing seizure
eterioration (Pennell, 2003; Pirie et al., 2014). Both the
LAE and the American Academy of Neurology cur-
ently recommend TDM during pregnancy in women
n an AED known to undergo substantial clearance
hanges, including lamotrigine, levetiracetam, oxcar-
azepine and phenytoin. When a pre-pregnancy level
s unknown, increasing the dose, at least in women
ith a history of tonic-clonic seizures, should be con-
idered in any case (Tomson et al., 2019). When AED
oses have been increased during pregnancy, tapering
fter delivery will usually be required. TDM may also
e useful if there is concern about toxicity during this
ime, although in practice the decision will usually be
ade on clinical grounds before any level is available.
he other important test to do in relation to preg-
ancy is ensuring adequate vitamin D status ideally
efore conception, but also during pregnancy. Vita-
in D is essential for foetal development, therefore
hecking 25-hydroxyvitamin D levels at least once
arly on, and supplementing accordingly, is recom-
ended (Hart et al., 2015, Roth et al., 2017). Folate
upplementation (all, at least 0.4 mg/day) is also rec-
mmended but does not require serum monitoring.
imilarly, there is no requirement for monitoring vita-
in K or clotting parameters in women, including
hose on enzyme-inducing AEDs. Oral or intramuscu-
ar vitamin K administration in neonates is standard
are for all women in many countries, and there is
o evidence that the historical practice of additionally
upplementing the mother during the last trimester is
ecessary (Sveberg et al., 2015; Panchaud et al., 2018).pileptic Disord, Vol. 22, No. 4, August 2020
ther considerations in rare
r unusual cases
range of rare but important neurometabolic disor-
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iscussion of which is beyond the scope of this article
nd will almost always require specialist assessment in
tertiary centre. Some are particularly important not
o miss, as AEDs will often be ineffective, whereas tar-
eted therapy for the underlying disorder, in the form
f supplements or dietary modifications, can substan-
ially improve outcomes.
lutamine transporter type 1 deficiency syndrome
Glut1DS): This classically presents in infancy with
eizures that are treatment-resistant or influenced by
asting, associated with developmental delay, acquired
icrocephaly and a range of movement disorders.
owever, a much broader phenotype, including later
nset and paroxysmal movement disorders, is also
ow recognized (De Giorgis and Veggiotti, 2013).
lut1 facilitates glucose transport across the blood-
rain barrier and the initial diagnostic step, feasible
orldwide, is a fasting lumbar puncture which will
how relatively low CSF glucose (hypoglycorrhachia)
ompared to blood glucose and a low-to-normal
actate level. Genetic confirmation by analysis of the
olute carrier family 2 (facilitated glucose transporter)
ember 1 (SLC2A1) gene may then be performed.
arly diagnosis is critical because it allows prompt
nitiation of treatment with a ketogenic diet (Klepper
nd Leiendecker, 2007; De Giorgis and Veggiotti, 2013).
itamin B6-dependent epilepsies: The B6 vitamins, in
articular pyridoxal-5’-phophate (PLP), are involved in
ver 70 human pathways, including amino acid and
eurotransmitter metabolism (Wilson et al., 2019). In
ny neonate or infant presenting with AED-resistant
eizures, often myoclonic in the first days of life,
lasma, urine and ideally CSF samples should be
ollected and frozen at -80◦C for biomarkers. Hypogly-
aemia and lactic acidosis may be present in the acute
hase, but testing should not delay a prompt empirical
rial of treatment with pyridoxine in the first instance,
ith next steps dependent on response. Later-
nset cases, including status epilepticus in adults,
ave also been reported but appear to be extremely
are.
itochondrial disorders are another important
roup, characteristically causing a combination of dif-
erent types of focal seizures and can pose a significant
isk of SE (Bindoff and Engelsen, 2012). Indicators to
onsider onward referral include seizures developing
n association with failure to thrive, developmental391
elay, ataxia and multiorgan involvement (Rahman,
012). Whilst none are yet treatable, some are asso-
iated with a higher risk of potentially fatal adverse
iver reactions with commonly used AEDs, such as
alproate. Raised serum and/or CSF lactate may be
nother clue, but in the acute setting, is non-specific.
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Case 1
A lady in her 40s with drug-resistant focal epilepsy
due to a cortical dysplasia presented in 2018
to her local hospital with a cluster of seizures.
She had undergone epilepsy surgery in child-
hood, with only partial benefit. She had been
on carbamazepine since early childhood, and
tried serial add-on therapies including pheno-
barbitone, valproate, clonazepam, acetazolamide,
pregabalin, phenytoin and levetiracetam without
benefit. For several years, she would have 5-10 focal
seizures/week, and weekly tonic-clonic seizures.
On a combination of carbamazepine, lamotrig-
ine and clobazam, she had been relatively stable
for four years with typically three focal seizures
and one focal-onset bilateral tonic-clonic seizure
a month, and occasionally a few weeks seizure-
free, and did not wanted to make further changes.
Attempts to lower the dose of carbamazepine had
been associated with deteriorations the past. On
presentation, she was found to have a sodium
level of 130 mmol/L without any other new symp-
toms. The local team, without consulting her regular
neurologist, decided to switch her carbamazepine
to levetiracetam, and later add lacosamide; her
seizures then became more frequent, and her mood
substantially deteriorated. There were multiple fur-
ther acute presentations, culminating in transfer to
the regional neurosciences centre for diagnostic
clarification and further management. Review of
her records, dating between 2011 and 2018, by
her regular treating neurologist identified that her
sodium level had ranged between 124 mmol/L
and 136 nmol/L with stable carbamazepine doses,
















A lady in her 20s presented with two nocturnal
tonic-clonic seizures, two months apart. A history
of episodic intense sudden-onset anxiety, height-
ened emotion and déjà vu sensations lasting up
to a minute was obtained, escalating in frequency
in the two weeks before each event. A diagnosis
of epilepsy was made clinically and treatment with
lamotrigine initiated. MRI was negative, and her
EEG showed rhythmic epileptiform discharges in
her left temporal lobe. She was appropriately coun-
selled about pregnancy and bone health, became
seizure-free without side effects on 50 mg twice
a day and was reluctant to increase it any further.
A pre-pregnancy trough level was documented at
1.8 mg/L. In 2011, she enquired about withdrawing
medication as part of planning pregnancy, and was
advised to wait until she had been free of seizures
for at least two years. She then represented, sev-
eral months later, already 24 weeks pregnant, having
had another cluster of focal seizures leading to a
bilateral tonic seizure, with a trough level of only
0.5 mg/L. Her lamotrigine was increased to 100 mg
twice a day, and she went on to deliver a healthy
boy without complications or further seizures. A
trough serum level on this dose the following year,
still seizure-free, was 3.1 mg/L, and she elected to
remain on this with advice to let us know if she
was planning a further pregnancy. She reported that
she was again pregnant six years later, having her-
self (without advice) reduced the dose to 50 mg,
twice a day, the preceding year. A review of events
in the previous pregnancy, later supported by a first-
trimester trough level of <1 mg/L, persuaded her to
increase the dose to 100 mg, twice a day. A second-
trimester level was still low at <1 mg/L, and despite
being seizure-free, she elected to increase the dose
further to 150 mg, twice a day. She remained seizure-
free throughout the pregnancy, delivering a healthy




any associated symptoms. Both levetiracetam and
lacosamide were withdrawn, and eslicarbazepine
introduced with a substantial reduction in her
seizures, no further acute presentations since, and
the last recorded sodium level at 133 mmol/L.
iagnosis is based on genetic testing, initially using
lood to identify common mutations, but not infre-
uently, a muscle sample is required for genetic and
iochemical analysis.
verolimus for tuberous sclerosis complex (TSC). The
TOR inhibitor (mammalian Target of Rapamycin),
verolimus, which has been used for various benign92
umours associated with TSC for some years, has
ore recently been licensed for the treatment of
rug-resistant epilepsy associated with TSC (French
t al., 2016). As well as monitoring of serum levels to
etermine appropriate dose, adverse events include
yperglycaemia, hypercholesterolaemia, hypertriglyc-








day, after delivery, in two steps, and to date, she has
continued with this amount of drug.
egular monitoring on initiation and throughout
reatment, alongside standard haematological, bone
ealth, renal and liver function tests.
ther genetic testing. Epilepsy genetics is a rapidly
eveloping field and has not been covered in this arti-
le, but is becoming increasingly relevant in specialistEpileptic Disord, Vol. 22, No. 4, August 2020
ractice both for diagnosis and drug development, and
n some instances with respect to informing treatment
hoices. This has been recently reviewed elsewhere
Myers et al., 2019).







































































































aboratory investigations, whilst not essential to the
iagnosis of seizures or epilepsy, can be fundamental
o determining the cause and guiding management.
ver 50% of first seizures have an acute symptomatic
ause, including a range of metabolic, toxic or infec-
ious causes. The same triggers can precipitate status
pilepticus, either de novo or as part of a deteriora-
ion of control in individuals with established epilepsy.
ome, such as hypoglycaemia or severe hypona-
raemia can be fatal without prompt identification and
reatment. Failure to identify seizures associated with
ecreational drug or alcohol misuse can lead to inap-
ropriate AED treatment, as well as a missed opportu-
ity for more appropriate intervention. In individuals
ith established epilepsy on treatment, some labora-
ory monitoring is desirable at least occasionally, in
articular, in relation to bone health, as well as in situ-
tions where changes in AED clearance or metabolism
re likely (extremes of age, pregnancy, comorbid dis-
rders of renal or hepatic function). For any clinician
anaging people with epilepsy, awareness of the com-
oner derangements associated with individual AEDs
s essential to guide practice. A very broad range
f neurometabolic disorders can be associated with
pilepsy, which may manifest as a presenting feature.
wareness of suggestive clinical features and onward
eferral to specialist centres is recommended, though
n resource-poor settings, trials of dietary treatments
r supplements may be appropriate as a first step. 
upplementary data
ummary didactic slides are available on the
ww.epilepticdisorders.com website.
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TEST YOURSELF
EDUCATION
(1) A 63-year-old man presents to hospital at midday having had a first witnessed self-limiting tonic-clonic
seizure, 45 minutes before arrival. He has been previously well other than hypertension for which he takes
a thiazide diuretic. He had celebrated his 40th wedding anniversary the previous night. His wife says he had
about 8 units of alcohol, and usually drinks 3-4 units, two or three times a week. Initial blood tests are normal
other than a random glucose level of 14 mM/L, a sodium level of 126 mg/dl and a creatine kinase level of 334 U/L.
Serum alcohol is undetectable. How is this event best characterised?
A. Alcohol-withdrawal seizure
B. First unprovoked seizure
C. Seizure provoked by hyperglycaemia
D. Seizure provoked by hyponatraemia
(2) A 27-year-old women with focal epilepsy of unknown cause, with previous focal-onset bilateral tonic-
clonic seizures, with onset at age 17, has been in remission on lamotrigine monotherapy for eight years. A
pre-pregnancy trough level was documented at 4.2 mcg/ml on 100 mg twice a day. She is newly pregnant
and started taking a folate supplement before she conceived. Which of the following blood tests should be






(3) A 15-year-old girl is sent to the emergency department having collapsed at school. She had been standing
in a longer-than-usual queue for lunch, felt lightheaded and the next thing she remembers is her friends all
standing around her looking shocked and calling for help. She felt too weak to get up for about 10 minutes,
and was embarrassed at having wet herself, but had no other symptoms. Witnesses say she just collapsed
suddenly, had some jerky stiff movements for about 10 seconds, was unconscious for less than a minute and
looked pale. Which blood tests will help confirm this was syncope and not a seizure?
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C. Full blood count
D. None
E. ProlactinEpileptic Disord, Vol. 22, No. 4, August 2020
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(4) A 38-year-old man was found collapsed and convulsing in the street by passers-by. Witness accounts from
the paramedics confirm this was a tonic-clonic seizure, which they terminated with intravenous lorazepam. He
is still very confused and post-ictal some hours later in hospital. His creatine kinase is elevated at 780 units/L
two hours after he was found. Why is knowing his CK is elevated useful for his management?
A. It confirms this must have been an epileptic seizure and not dissociative
B. It indicates an underlying muscle disease that needs investigating further
C. It indicates that this was status epilepticus and not a self-limiting seizure
D. The level might continue to rise and cause kidney injury, thus requiring monitoring
(5) A 73-year-old woman presents with new-onset convulsive status epilepticus with a background of cere-
brovascular disease, and having failed to respond to benzodiazepines and intravenous valproate is intubated,
sedated and admitted to intensive care. She had convulsed for around 45 minutes in total. The emergency
department had already checked full blood count, urea and electrolytes, calcium, magnesium and glucose
which were normal. ICU have checked her blood gases. She is afebrile. Which additional blood tests are





E. Liver function tests
(6) A 41-year-old man is called in for a review with his primary care physician. He has juvenile myoclonic
epilepsy which has been in remission for 22 years on valproate at 600 mg/day. He has collected prescriptions
regularly, but not attended in person for over four years. He is otherwise entirely healthy. Which laboratory
investigations would be important to check? You may select one or more answers.
A. Ammonia
B. Full blood count
C. Liver function tests
D. Valproate levels
E. Vitamin D
(7) A 52-year-old Chinese woman was started on carbamazepine five weeks ago, and is now on 300 mg twice
a day, without any baseline blood screening tests. She has a new diagnosis of focal epilepsy attributed to
a previous traumatic brain injury. She presents to her primary care physician with a severe sore throat and
temperature. Which is the most important blood test to now request urgently? You may select one or more
answers.
A. Full blood count
B. Liver function tests
C. Urea and electrolytes
D. HLA-B*1502 status
E. Carbamazepine level
(8) A 22-year-old man with severe intellectual disabilities and drug-resistant epilepsy has been commenced
on topiramate at 150 mg/day in addition to his longstanding lamotrigine. His mother reports that he keeps
flapping his hands unusually, and seems agitated and distressed but she does not know why. What blood test
might indicate that topiramate is causing symptoms in his hands?
A. Ammonia
B. Bicarbonate
C. Full blood count
D. Liver function tests
E. Topiramate levels
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(9) A 51-year-old woman is brought in to hospital having had a middle cerebral artery stroke, successfully
treated with thrombolysis. She has a background of focal epilepsy of unknown cause which has been well
controlled since onset (age 40 years) on carbamazepine at 400 mg twice a day, with no other medication. Her
sodium level is low at 129 nmol/L, without any associated symptoms. What would you recommend with respect
to her antiepileptic drug treatment when discussing this result with her?
A. Lower the dose of carbamazepine
B. No change, this is common and not of concern
C. Switch her to an alternative drug
D. Withdraw the drug, as she is seizure-free
(10) A 19-year-old man with generalized epilepsy and tonic-clonic seizures on awakening had been seizure-
free for two years on lamotrigine at 150 mg/day, but is brought into hospital at 9 a.m. by his girlfriend having
had seizures on three consecutive mornings; two only 15 minutes apart that morning. He is otherwise well,
reports taking his medication regularly, and does not report any lifestyle changes. You start taking some blood




D. Liver function tests
E. Urea and electrolytes
Note: Reading the manuscript provides an answer to all questions. Correct answers may be accessed on the
website, www.epilepticdisorders.com, under the section “The EpiCentre”.
